Protagenic Therapeutics, Inc. (PTIX) Research

Protagenic Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to the research and development of novel treatments designed to address neuropsychiatric and mood conditions exacerbated by stress. Foremost among its investigational products is PT00114, a laboratory-synthesized version of the teneurin carboxy-terminal associated peptide. This compound functions by emulating an innate brain signaling peptide, known for its ability to temper exaggerated stress reactions. The company's headquarters are located in New York, New York.

Market snapshot

Symbol
PTIX
Price
$0.41
Day change
0.00%
Market cap
$742.2K
P/E ratio
-0.15x
52-week range
0.25-6.2
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Artelo Biosciences, Inc. (ARTL)
  • Carisma Therapeutics, Inc. (CARM)
  • GT Biopharma, Inc. (GTBP)
  • Indaptus Therapeutics, Inc. (INDP)
  • Lipella Pharmaceuticals Inc. (LIPO)
  • Psyence Biomedical Ltd. (PBM)
  • Revelation Biosciences, Inc. (REVB)
  • Salarius Pharmaceuticals, Inc. (SLRX)

Recent insider activity

  • EVANS BARRETT — trade (0 shares) on 2025-05-15
  • EVANS BARRETT — trade (0 shares) on 2025-05-15
  • EVANS BARRETT — trade (0 shares) on 2025-05-15
  • EVANS BARRETT — trade (0 shares) on 2025-05-15
  • EVANS BARRETT — trade (0 shares) on 2025-05-15

Open Protagenic Therapeutics, Inc. (PTIX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.